cth522
Vaccineexperimental
Clinical trial activity
4 trials · 4 clinical orgs · 0 marketing orgs
Phase 1
4
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Jul 1, 2016 (NCT02787109)
Timeline
2010s
- Jan 1, 2016
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
- ChlamydiaImmunity, active
Chlamydia immunity, active
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- cth522
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT04451954 | Phase 1 | Jul 2, 2020 | Sanofi-Aventis |
| NCT04144179 | Phase 1 | Nov 7, 2019 | Sanofi-Aventis |
| NCT03926728 | Phase 1 | Sep 30, 2019 | Imperial College London, Statens Serum Institut |
| NCT02787109 | Phase 1 | Jul 1, 2016 | Statens Serum Institut, University of London |
Showing 4 of 4 trials
Page 1 / 1
Organizations
Research & Development (4)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Sanofi-Aventis | For profit | 2 | 2 | 1 | 2019 |
| Statens Serum Institut | Academic/Hospital | 2 | 2 | 1 | 2016 |
| Imperial College London | Academic/Hospital | 1 | 0 | 1 | 2019 |
| University of London | Academic/Hospital | 1 | 0 | 1 | 2016 |
4 organizations
Page 1 / 1